Biological
Vibostolimab clinical trials
Also written MK-7684.
- studies test it
- 8
- open now
- 0
- in phase 3
- 4
- first study started
- 2016
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 3
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Pembrolizumab (8) · Favezelimab (3) · Pembrolizumab/Quavonlimab MK-1308A (2) · Tretinoin (1) · Vibostolimab/Pembrolizumab MK-7684A (1)
Studies
Open first, then newest update. How each study uses vibostolimab is read from its arms, and is right about nine times in ten.
Testing it · 8
- Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)TerminatedPhase 3Merck Sharp & Dohme LLCNCT04738487Written as Pembrolizumab/Vibostolimab
- Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)TerminatedPhase 3Merck Sharp & Dohme LLCNCT05226598Written as Pembrolizumab/Vibostolimab
- A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)TerminatedPhase 3Merck Sharp & Dohme LLCNCT05665595Written as Pembrolizumab/Vibostolimab
- Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)CompletedPhase 3Merck Sharp & Dohme LLCNCT05298423Written as pembrolizumab/vibostolimab
- Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT04895722Written as Pembrolizumab/Vibostolimab
- Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04305054Written as Vibostolimab
- Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)CompletedPhase 1Merck Sharp & Dohme LLCNCT02964013Written as vibostolimab
- A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)WithdrawnPhase 1/2Merck Sharp & Dohme LLCNCT06395090Written as Vibostolimab
Given in every arm · 3 — vibostolimab is usual care beside what is tested
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT04165070Written as Vibostolimab
- Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04305041Written as Vibostolimab
- Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04303169Written as Vibostolimab
Codes
What other systems call vibostolimab · ClinicalTrials.gg INT015145
- UNII (FDA) 5XO3JF0FEKVIBOSTOLIMABOne source FDA
- NCI Thesaurus C140041VibostolimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5XO3JF0FEK | VIBOSTOLIMAB | One source FDA |
| NCI Thesaurus | C140041 | Vibostolimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.